Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan 18;131(3):301-310.
doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thierry Facon  1 , Meletios A Dimopoulos  2 , Angela Dispenzieri  3 , John V Catalano  4 , Andrew Belch  5 , Michele Cavo  6 , Antonello Pinto  7 , Katja Weisel  8 , Heinz Ludwig  9 , Nizar J Bahlis  10 , Anne Banos  11 , Mourad Tiab  12 , Michel Delforge  13 , Jamie D Cavenagh  14 , Catarina Geraldes  15 , Je-Jung Lee  16 , Christine Chen  17 , Albert Oriol  18 , Javier De La Rubia  19 , Darrell White  20 , Daniel Binder  21 , Jin Lu  22 , Kenneth C Anderson  23 , Philippe Moreau  24 , Michel Attal  25 , Aurore Perrot  26 , Bertrand Arnulf  27 , Lugui Qiu  28 , Murielle Roussel  29 , Eileen Boyle  1 , Salomon Manier  1 , Mohamad Mohty  30 , Herve Avet-Loiseau  31 , Xavier Leleu  32 , Annette Ervin-Haynes  33 , Guang Chen  33 , Vanessa Houck  33 , Lotfi Benboubker  34 , Cyrille Hulin  35
Affiliations
Clinical Trial

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thierry Facon et al. Blood. .

Abstract

This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.59-0.79; P < .00001) and was similarly extended vs Rd18. Median OS was 10 months longer with Rd continuous vs MPT (59.1 vs 49.1 months; HR, 0.78; 95% CI, 0.67-0.92; P = .0023), and similar with Rd18 (62.3 months). In patients achieving complete or very good partial responses, Rd continuous had an ≈30-month longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over half of all patients who received second-line treatment were given a bortezomib-based therapy. Second-line outcomes were improved in patients receiving bortezomib after Rd continuous and Rd18 vs after MPT. No new safety concerns, including risk for secondary malignancies, were observed. Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible NDMM. This trial was registered at www.clinicaltrials.gov as #NCT00689936 and EudraCT as 2007-004823-39.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: T.F. reports advisory board fees from Amgen, Celgene, Janssen, Karyopharm, Pharmamar, and Takeda and speakers bureau fees from Amgen, Celgene, Janssen, and Takeda; M.A.D. reports honoraria and consulting/advisory fees from Amgen, Celgene, Janssen, and Takeda; A.D. reports grants from Alnylam, Celgene, Pfizer, Prothena, and Takeda; M.C. reports honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; A. Pinto reports honoraria from Celgene, Spectrum, and Takeda and research funding from Takeda; K.W. reports research funding from Celgene and Janssen and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Onyx, and Takeda and advisory board membership for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Onyx, and Takeda; H.L. reports consulting or advisory fees and speakers bureau fees from Amgen, Bristol-Myers Squibb, Celgene, and Janssen and research funding from Takeda; N.J.B. reports honoraria, consulting, or advisory fees and travel expenses from Amgen, Celgene, Janssen, and Takeda and research funding and fees for expert testimony from Celgene and Janssen; M.D. reports research grants, consultancy fees, and speaker’s honoraria from Celgene and Janssen, consultancy fees and speaker’s honoraria from Amgen, and consultancy fees from Bristol-Myers Squibb and Takeda; C.G. reports honoraria from and advisory board membership for Amgen, Bristol-Myers Squibb, Celgene, and Janssen; C.C. reports consulting for and research funding and honoraria from Celgene; A.O. reports advisory board fees from Amgen and Janssen; D.W. reports grants from Celgene and grants and personal fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda; K.C.A. reports advisory board fees from Bristol-Myers Squibb, Celgene, Gilead, and Millennium; P.M. reports honoraria from Bristol-Myers Squibb, Celgene, Janssen, and Takeda; A. Perrot reports honoraria and consulting fees from Amgen, Celgene, Janssen, Novartis, and Takeda; M.R. reports grants, personal fees, and nonfinancial support from Amgen, Celgene, and Janssen; E.B. reports advisory board fees from Celgene; M.M. reports personal fees from Celgene; A.E.-H. reports employment and stock options from Celgene; G.C. reports employment, stock options, and travel expenses from Celgene; V.H. reports employment from Celgene; L.B. reports grants, personal fees, and nonfinancial support from Celgene and Janssen, personal fees and nonfinancial support from Amgen, and personal fees from Takeda; C.H. reports honoraria from Celgene; the remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
PFS.
Figure 2.
Figure 2.
Effect of patient subgroup on PFS. *Number of events per number of patients. †Complete cytogenetics profile for 501 patients (248 in Rd continuous and 253 in MPT); high-risk cytogenetics included t(4;14), t(14;16), and del(17p). cont, continuous; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System.
Figure 3.
Figure 3.
PFS by response subgroup. PFS in patients achieving ≥VGPR (left) and ≥PR (right).
Figure 4.
Figure 4.
OS.
Figure 5.
Figure 5.
Effect of patient subgroup on OS. *Number of events per number of patients. †Complete cytogenetics profile for 501 patients (248 in Rd continuous and 253 in MPT); high-risk cytogenetics included t(4;14), t(14;16), and del(17p).
Figure 6.
Figure 6.
TTNT.
See this image and copyright information in PMC

References

    1. Revlimid® (lenalidomide) [package insert]. Summit, NJ. Celgene Corporation. 2017.
    1. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309. - PMC - PubMed
    1. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326-2335. - PMC - PubMed
    1. Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5(10):e354. - PMC - PubMed
    1. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-305. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data